News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Comparative Effectiveness of Enlarged Prostate Treatments in Medicare-eligible Men

Cost Comparison of Finasteride and Dutasteride for Enlarged Prostate in a Managed Care Setting Among Medicare-aged Men

ByMichael Naslund, MD, MBA,Michael T. Eaddy, PharmD, PhD,Eric J. Kruep, PharmD, MS,Susan L. Hogue, PharmD, MPH

May 1st 2008

Comparative Analysis of Alpha-blocker Utilization in Combination With 5-Alpha Reductase Inhibitors for Enlarged Prostate in a Managed Care Setting Among Medicare-aged Men

ByMuta M. Issa, MD, MBA,Pei-Jung Lin, PhD,Michael T. Eaddy, PharmD, PhD,Manan B. Shah, PharmD, PhD,E. Anne Davis, PharmD, MS

May 1st 2008

Dutasteride vs Finasteride: Assessment of Differences in Acute Urinary Retention Rates and Surgical Risk Outcomes in an Elderly Population Aged ≥65 Years

ByThomas C. Fenter, MD,E. Anne Davis, PharmD, MS,Manan B. Shah, PharmD, PhD,Pei-Jung Lin, PhD

May 1st 2008

5-Alpha Reductase Inhibitors in Men With an Enlarged Prostate: An Evaluation of Outcomes and Therapeutic Alternatives

ByMichael Naslund, MD, MBA,Timothy S. Regan, BPharm, RPh, CPh,Christine Ong, PharmD, MBA, BS,Susan L. Hogue, PharmD, MPH

May 1st 2008

Participating Faculty

By

April 30th 2008

Trending on AJMC

DOJ Abandons Olmstead Defense as Texas v Kennedy Advances

FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes

Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis

FDA Approves Rusfertide to Treat Erythrocytosis In Polycythemia Vera

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk